Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir

BACKGROUND: Ganciclovir/valganciclovir is currently indicated during the first 6 months of life in symptomatic children with congenital cytomegalovirus (CMV) infection. However, this treatment may have the potential to induce mitochondrial toxicity due to off-target inhibition of DNA-polymerases. Si...

Full description

Bibliographic Details
Main Authors: Cantó-Santos, J. (Author), Cardellach, F. (Author), Fortuny, C. (Author), García-García, F.J (Author), Garrabou, G. (Author), Grau, J.M (Author), Morén, C. (Author), Noguera-Julian, A. (Author), Ortiz-Gracia, A. (Author), Ríos, M. (Author), Sánchez, E. (Author), Tobías, E. (Author), Valls-Roca, L. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
cell biology
child development
deafness
toxicology
virology
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items